Home > Boards > US Listed > Biotechs > BIONDVAX PHARMACUETICALS LTD (BVXV)

Could the flu become history? A conversation with

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 109
Posts 24,068
Boards Moderated 14
Alias Born 02/07/04
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/1/2020 8:20:36 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/1/2020 6:32:00 AM
Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial PR Newswire (US) - 7/1/2020 6:00:00 AM
BiondVax Announces First Quarter 2020 Financial Results PR Newswire (US) - 6/30/2020 4:01:00 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 6/22/2020 1:37:36 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/12/2020 8:11:32 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 6/12/2020 8:04:57 AM
BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update PR Newswire (US) - 6/12/2020 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/10/2020 7:48:38 AM
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoin... PR Newswire (US) - 6/10/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/20/2020 7:44:36 AM
BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants PR Newswire (US) - 5/20/2020 6:30:00 AM
Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... Edgar (US Regulatory) - 5/13/2020 4:34:19 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/4/2020 10:48:44 AM
BiondVax Announces Upcoming Expiration of Public Warrants PR Newswire (US) - 5/4/2020 6:30:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/30/2020 9:40:42 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/24/2020 4:28:59 PM
New Directors Elected to BiondVax's Board of Directors PR Newswire (US) - 3/24/2020 4:01:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 3/19/2020 1:06:02 PM
BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial PR Newswire (US) - 3/19/2020 7:15:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/25/2020 12:42:30 PM
Amended Report of Foreign Issuer (6-k/a) Edgar (US Regulatory) - 2/10/2020 5:22:43 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/10/2020 11:15:24 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/5/2020 3:25:39 PM
Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Va... PR Newswire (US) - 2/5/2020 1:00:00 PM
midastouch017   Friday, 05/08/20 05:52:33 AM
Re: None
Post # of 373 
Could the flu become history? A conversation with Prof. Ruth Arnon on May 12

WHEN: Tuesday, May 12, 2020 12:00 pm - 1:00 pm

WHERE: Online via Zoom (details to be provided upon registration)
Register for the event now
About this event
Join us on Tuesday, May 12 at 12 p.m. ET, for an online discussion with Prof. Ruth Arnon, from Weizmann’s Department of Immunology, who has spearheaded a universal influenza vaccine.
As a renowned immunologist, Prof. Arnon previously co-developed a multiple sclerosis (MS) drug that commands a third of the market worldwide. She is now undergoing the third and final phase in the clinical trial process for an influenza vaccine, which would protect people from the flu for many years and against multiple strains. Results are expected later this year.
Since the flu changes every year, new vaccines continually have to be made and developed for the current strain. After working on this project for two decades, Prof. Arnon and colleagues now have a vaccine they believe will be ready to go public, upon approval from regulators.
The event and question and answer period will be moderated by Dr. Arthur Slutsky, Keenan Chair in Medicine at St. Michael’s Hospital and Professor of Medicine, Surgery and Biomedical Engineering at the University of Toronto. Dr. Slutsky also serves on the Weizmann Canada Board of Directors.
We are so grateful for your support and participation.
DATE | Tuesday, May 12, 2020
TIME | Join by 11:50 a.m. ET, presentation will begin at 12:00 p.m. ET (noon)
LOCATION | Online via Zoom (details to be provided upon registration)
Please note that turning on your video camera for the event is optional. We hope you will join us in the capacity in which you feel comfortable.
This is a free event, but space is limited.

https://www.weizmann.ca/events/could-the-flu-become-history-a-conversation-with-prof-ruth-arnon-on-may-12/

Hopefully new info will be available?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist